Inverse Agonists: Drugs That Do the Opposite

The traditional pharmacological framework divided receptor-interacting drugs into two categories: agonists (which activate receptors) and antagonists (which block them). The discovery that many receptors have constitutive activity — they are partially active even without any ligand — revealed the existence of a third category: inverse agonists, drugs that not only block agonist binding but actively reduce receptor activity below the basal (unoccupied) level. The concept of inverse agonism has significantly complicated the pharmacological landscape and has direct clinical relevance in several therapeutic areas.

Constitutive Receptor Activity

In the two-state receptor model, receptors exist in equilibrium between inactive (R) and active (R*) conformations even in the absence of any ligand. At equilibrium, if even a small percentage of receptors spontaneously adopt the R* conformation, there is constitutive (ligand-independent) receptor activity. For many G protein-coupled receptors (GPCRs), this constitutive activity was long considered negligible in physiological contexts, but it became apparent with the development of receptor expression systems where high receptor densities amplify constitutive activity, and in pathological contexts where receptor mutations constitutively activate signaling (gain-of-function mutations in GPCRs are found in thyroid adenomas, retinitis pigmentosa, and various cancers).

In the presence of constitutive activity, a drug's pharmacological profile depends on which receptor state it preferentially stabilizes: full agonists stabilize R* completely; partial agonists partially stabilize R*; neutral antagonists have equal affinity for R and R* (and block agonist access without affecting basal activity); and inverse agonists preferentially stabilize R (inactive), reducing receptor activity below the constitutive baseline.

Molecular Mechanisms of Inverse Agonism

Inverse agonists typically bind to an allosteric site or the orthosteric binding pocket of the receptor in a conformation that stabilizes inactive receptor states. Crystallographic and cryo-EM studies of GPCR-inverse agonist complexes have revealed that inverse agonists often adopt a binding mode that prevents the conformational changes (particularly in transmembrane helices TM5 and TM6) required for G protein coupling, effectively locking the receptor in an inactive configuration. The strength of inverse agonism — the degree to which the drug reduces activity below baseline — depends on both the drug's binding mode and the degree of constitutive receptor activity in the tissue of interest.

Clinical Inverse Agonists

Many drugs traditionally classified as "neutral antagonists" are now recognized as inverse agonists in systems with constitutive receptor activity. Beta-blockers used in heart failure — bisoprolol, carvedilol, metoprolol — are inverse agonists at beta-1 adrenergic receptors, reducing constitutive receptor activity in failing cardiomyocytes where receptor density is elevated. The survival benefit of beta-blockers in heart failure may be partly attributable to their inverse agonism reducing the energetically costly constitutive beta-1 adrenergic signaling in hypertrophied, stressed myocardium — an explanation that emerged only after the inverse agonist concept became established.

Histamine H2 receptor inverse agonists include ranitidine and famotidine — antacids used to treat peptic ulcers and GERD. These drugs were originally classified as H2 antagonists, but in systems with constitutive H2 receptor activity (particularly heterologously expressed systems), they reduce basal acid secretion below the unstimulated baseline, indicating inverse agonism. Cannabinoid CB1 receptor inverse agonists (including the withdrawn anti-obesity drug rimonabant) suppress both agonist-stimulated and constitutive CB1 signaling, producing effects opposite to cannabis — reduced appetite, increased energy expenditure, and anxiety (which contributed to rimonabant's withdrawal due to psychiatric adverse effects). For the related concept of partial agonism and its clinical applications, revisit our article on full agonists vs partial agonists.

For more information, visit our homepage or our resources section.